Stephens Consulting, LLC Protagonist Therapeutics, Inc Transaction History
Stephens Consulting, LLC
- $399 Billion
- Q1 2025
A detailed history of Stephens Consulting, LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Stephens Consulting, LLC holds 20 shares of PTGX stock, worth $916. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20Holding current value
$916% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PTGX
# of Institutions
252Shares Held
58MCall Options Held
226KPut Options Held
218K-
Farallon Capital Management LLC San Francisco, CA5.93MShares$272 Million1.22% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$264 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.5MShares$252 Million3.46% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$193 Million0.0% of portfolio
-
State Street Corp Boston, MA3.33MShares$153 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.25B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...